Stocktoria
Ensysce Biosciences, Inc. ENSC
Ensysce Biosciences, Inc. (ENSC) earns a Piotroski F-score of 0/9 (weak financial health). It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 0/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ENSC | Ensysce Biosciences, Inc. | 0/9 | — | — | — |
| PCYN | PROCYON CORP | 3/9 | 3.03 | — | — |
| ABEO | ABEONA THERAPEUTICS INC. | 4/9 | -5.75 | 4.5 | — |
| CPHI | CHINA PHARMA HOLDINGS, INC. | 4/9 | -3.85 | — | — |
| ATAI | AtaiBeckley Inc. | 4/9 | — | — | — |
| CRVO | CervoMed Inc. | 1/9 | -12.9 | — | — |
| KRRO | Korro Bio, Inc. | 2/9 | -13.3 | — | — |
About Ensysce Biosciences, Inc.
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder. Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.
FAQ
Is ENSC financially healthy?
Ensysce Biosciences, Inc.'s Piotroski F-score is 0/9 (8–9 is excellent, 0–3 weak).
Does ENSC pay a dividend?
No, Ensysce Biosciences, Inc. does not currently pay a dividend.
What is the analyst price target for ENSC?
The average Wall-Street price target for Ensysce Biosciences, Inc. is $16.45, about 4025.9% above the recent price, from 1 analysts.
Is ENSC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Ensysce Biosciences, Inc.: a Piotroski F-score of 0/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.